or Try an Advanced Search...

    Technical Analysis for RNXT - RenovoRx, Inc.

    Grade Last Price % Change Price Change
    F 1.21 1.08% 0.01
    RNXT closed up 1.08 percent on Wednesday, April 24, 2024, on 8 percent of normal volume.
    Earnings due: May 13
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical RNXT trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Bollinger Band Squeeze Range Contraction 1.08%
    NR7 Range Contraction 1.08%
    Narrow Range Bar Range Contraction 1.08%
    BB Squeeze Started Range Contraction 1.08%
    Inside Day Range Contraction 1.08%
    Gapped Down Weakness 1.08%
    20 DMA Resistance Bearish -1.38%
    Older End-of-Day Signals for RNXT ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 4 hours ago
    60 Minute Opening Range Breakout about 4 hours ago
    Up 2% about 4 hours ago
    Possible NR7 about 4 hours ago
    10 DMA Support about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    RNXT Chart by TradingView
    Basic chart:

    Profile

    RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trial for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Gastrointestinal Cancer Evofosfamide Gemcitabine

    Is RNXT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 15 RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
    Apr 5 RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
    Mar 12 RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
    Mar 8 RenovoRx promotes Leesa Gentry to chief clinical officer
    Mar 8 RenovoRx Highlights Key Leadership Promotions
    Feb 6 RenovoRx CEO Issues Letter to Shareholders
    Jan 29 RenovoRx closes $6.1M private placement
    Jan 29 RenovoRx Closes $6.1 Million Private Placement
    Dec 21 RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
    Dec 19 RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
    See more RNXT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.29
    52 Week Low 0.5488
    Average Volume 42,657
    200-Day Moving Average 1.36
    50-Day Moving Average 1.39
    20-Day Moving Average 1.22
    10-Day Moving Average 1.20
    Average True Range 0.13
    RSI (14) 45.65
    ADX 12.79
    +DI 20.03
    -DI 13.89
    Chandelier Exit (Long, 3 ATRs) 1.16
    Chandelier Exit (Short, 3 ATRs) 1.50
    Upper Bollinger Bands 1.35
    Lower Bollinger Band 1.09
    Percent B (%b) 0.46
    BandWidth 21.08
    MACD Line -0.05
    MACD Signal Line -0.07
    MACD Histogram 0.0104
    Fundamentals Value
    Market Cap 20.41 Million
    Num Shares 16.8 Million
    EPS -0.92
    Price-to-Earnings (P/E) Ratio -1.32
    Price-to-Sales 0.00
    Price-to-Book 4347.25
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.27
    Resistance 3 (R3) 1.27 1.25 1.26
    Resistance 2 (R2) 1.25 1.24 1.25 1.26
    Resistance 1 (R1) 1.23 1.23 1.22 1.23 1.26
    Pivot Point 1.21 1.21 1.21 1.21 1.21
    Support 1 (S1) 1.19 1.20 1.18 1.19 1.17
    Support 2 (S2) 1.17 1.19 1.17 1.17
    Support 3 (S3) 1.15 1.17 1.16
    Support 4 (S4) 1.15